RxDoctor Payments Data

Guido Leon, MD

Cardiovascular Disease · Las Cruces, NMNPI 1841365194

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.0% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Medtronic at 41.5% of the total. Reporting peaked in 2021 at $328 and has fallen 89.3% since, to $35 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in NM, where the typical reported total is $1,223.

$1,257in general payments, 2019–2025

Across 65 payments — averaging $19.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$522
  • Abbott$405
  • Boston Scientific$123
  • Abiomed$91
  • Novartis$47
  • Chiesi USA, Inc.$23
  • plus $47 from 3 others

What the payments were for

  • Food & beverage$1,24599%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)28$522
Abbott22$405
Boston Scientific6$123
Abiomed2$91
Novartis2$47
Chiesi USA, Inc.2$23
Gilead1$17
Novo Nordisk1$15
Johnson & Johnson1$14

How this compares

$1,257 in reported general payments places this provider in the 50th percentile of 101 cardiovascular disease providers in New Mexico.

See all cardiovascular disease providers in New Mexico

Medicare billing

Part B allowed, 2024
$353,971
Medicare patients
571
Services billed
3,649

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban391$536,747
EntrestoSacubitril/Valsartan56$102,206
XareltoRivaroxaban69$83,631
Prasugrel Hcl229$22,760
JanuviaSitagliptin Phosphate18$18,732
Metoprolol Succinate642$9,493
Potassium Chloride444$7,984
ClopidogrelClopidogrel Bisulfate575$6,572
Prazosin Hcl89$6,476
Olmesartan Medoxomil371$5,495
Rosuvastatin Calcium307$4,422
Diltiazem 24hr Er (Cd)Diltiazem Hcl147$4,354
Digoxin149$4,181
Nifedipine ErNifedipine117$3,993
Colchicine41$3,739

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$47$102,20656 claims
Johnson & JohnsonXarelto$14$83,63169 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 101 cardiovascular disease providers in New Mexico.

Other cardiovascular disease in Las Cruces

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →